Immatics (NASDAQ: IMTX) files Q2 2025 interim report and business update

Rhea-AI Filing Summary

Immatics N.V. submitted a Form 6-K as a foreign private issuer to furnish materials related to its second quarter 2025 reporting. The company issued an interim report covering the three- and six-month period ended June 30, 2025, a press release with second quarter 2025 financial results and a business update, and an updated corporate investor presentation.

The interim report is attached as Exhibit 99.1, the press release as Exhibit 99.2, and the presentation as Exhibit 99.3. The interim report and the core portions of this Form 6-K (excluding the press release and presentation) are incorporated by reference into Immatics’ existing Form S-8 and Form F-3 registration statements, meaning those offering documents now formally include this updated interim information.

20250001809196June 30, 2025falseQ2December 310001809196imtx:ShorttermDepositsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001809196imtx:GeneralAndAdministrativeExpensesMember2024-01-012024-06-300001809196country:DKimtx:GenmabCollaborationAgreementMember2024-04-012024-06-300001809196imtx:ShorttermDepositsMember2025-06-300001809196imtx:ResearchAndDevelopmentExpensesMember2024-04-012024-06-300001809196ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2024-12-310001809196imtx:PerformanceBasedOptionsMember2024-12-310001809196imtx:GenmabCollaborationAgreementMember2024-01-012024-06-300001809196ifrs-full:SharePremiumMemberifrs-full:OrdinarySharesMember2025-01-012025-06-300001809196ifrs-full:IssuedCapitalMember2024-01-012024-06-300001809196country:USimtx:ModernaCollaborationAgreementMember2025-04-012025-06-300001809196imtx:MatchingStockOptionsMember2025-06-300001809196imtx:CollaborationAgreementsMember2024-04-012024-06-300001809196imtx:OfficeEquipmentAndInstallationsMember2025-01-012025-06-300001809196imtx:PerformanceBasedOptionsMember2025-04-012025-06-300001809196imtx:GrantedOnMarchTwoThousandAndTwentyOneMemberimtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember2025-01-012025-06-300001809196imtx:GeneralAndAdministrativeExpensesMember2024-04-012024-06-300001809196country:USimtx:BMSCollaborationAgreementMember2025-04-012025-06-300001809196ifrs-full:PreviouslyStatedMember2023-12-310001809196ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001809196country:DKimtx:GenmabCollaborationAgreementMember2025-01-012025-06-300001809196imtx:LiabilitiesForWarrantsMember2024-12-310001809196ifrs-full:OtherReservesMember2024-01-012024-06-300001809196ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2024-04-012024-06-300001809196imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember2025-06-300001809196imtx:GrantedOnFebruaryTwoThousandAndTwentyFourMemberimtx:PerformanceBasedOptionsMember2025-01-012025-06-300001809196ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2025-04-012025-06-300001809196ifrs-full:TopOfRangeMember2024-03-310001809196ifrs-full:RetainedEarningsMember2024-12-3100018091962025-01-012025-03-310001809196imtx:ReorganizationMember2025-06-300001809196imtx:IFRS7NotApplicableAndIFRS16Member2025-06-300001809196imtx:RentalLandMember2025-01-012025-06-300001809196imtx:OfficeEquipmentAndInstallationsMember2024-04-012024-06-300001809196ifrs-full:SharePremiumMember2024-01-012024-06-3000018091962025-04-012025-06-300001809196imtx:BmsAndModernaCollaborationAgreementMember2024-04-012024-06-300001809196ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberimtx:AccountsPayablesMember2024-12-310001809196imtx:OfficeEquipmentAndInstallationsMember2024-01-012024-06-300001809196imtx:PublicOfferingMember2024-01-222024-01-220001809196imtx:ResearchAndDevelopmentExpensesMember2025-01-012025-06-300001809196ifrs-full:SharePremiumMemberifrs-full:OrdinarySharesMember2024-01-012024-06-300001809196ifrs-full:RetainedEarningsMember2024-06-300001809196ifrs-full:BottomOfRangeMember2025-03-310001809196ifrs-full:OtherReservesMember2024-06-300001809196ifrs-full:OtherReservesMember2023-12-310001809196ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2024-12-310001809196country:DKimtx:GenmabCollaborationAgreementMember2024-01-012024-06-300001809196ifrs-full:RetainedEarningsMember2023-12-310001809196imtx:OtherCurrentLiabilityMember2025-06-300001809196ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberimtx:LiabilitiesForWarrantsMember2024-12-3100018091962023-12-310001809196ifrs-full:TradeReceivablesMember2025-06-300001809196ifrs-full:MajorOrdinaryShareTransactionsMemberimtx:PublicOfferingMember2024-01-220001809196ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2025-01-012025-06-300001809196imtx:OtherCurrentLiabilityMember2024-12-310001809196imtx:RentalLandMember2024-04-012024-06-300001809196ifrs-full:SharePremiumMemberimtx:PublicOfferingMember2024-01-222024-01-220001809196imtx:CollaborationAgreementsMember2024-01-012024-06-300001809196imtx:AuthorizationOfFinancialStatementsMember2025-08-132025-08-130001809196country:USimtx:ModernaCollaborationAgreementMember2024-04-012024-06-300001809196imtx:OtherCurrentNonCurrentAssetsMember2025-06-300001809196ifrs-full:IssuedCapitalMember2024-12-310001809196country:DKimtx:GenmabCollaborationAgreementMember2025-04-012025-06-300001809196ifrs-full:SharePremiumMemberifrs-full:OrdinarySharesMember2024-04-012024-06-300001809196ifrs-full:OtherReservesMember2025-06-300001809196imtx:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001809196imtx:OfficeEquipmentAndInstallationsMember2025-04-012025-06-3000018091962025-06-300001809196ifrs-full:OtherReservesMember2024-12-310001809196ifrs-full:PreviouslyStatedMember2024-04-012024-06-300001809196imtx:IFRS7NotApplicableAndIFRS16Memberifrs-full:LeaseLiabilitiesMember2025-06-300001809196ifrs-full:TradeReceivablesMember2024-12-310001809196ifrs-full:IssuedCapitalMember2024-06-300001809196country:USimtx:BMSCollaborationAgreementMember2024-04-012024-06-300001809196ifrs-full:BottomOfRangeMember2023-12-310001809196country:USimtx:ModernaCollaborationAgreementMember2024-01-012024-06-3000018091962024-01-012024-12-310001809196imtx:IFRS7NotApplicableAndIFRS16Memberimtx:OtherCurrentLiabilityMember2025-06-3000018091962024-04-012024-06-300001809196ifrs-full:IssuedCapitalMember2023-12-310001809196imtx:IFRS7NotApplicableAndIFRS16Memberimtx:OtherCurrentNonCurrentAssetsMember2025-06-300001809196ifrs-full:SharePremiumMember2024-06-300001809196imtx:AccountsPayablesMember2024-12-310001809196ifrs-full:RetainedEarningsMember2025-01-012025-06-300001809196ifrs-full:IssuedCapitalMemberimtx:PublicOfferingMember2024-01-222024-01-220001809196ifrs-full:IssuedCapitalMember2025-06-300001809196imtx:ConvertedOptionsMember2025-01-012025-06-300001809196ifrs-full:SharePremiumMember2024-12-310001809196ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001809196ifrs-full:LeaseLiabilitiesMember2024-12-310001809196imtx:OtherCurrentNonCurrentAssetsMember2024-12-310001809196country:DE2025-01-012025-06-300001809196ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-3000018091962024-12-310001809196imtx:ShorttermDepositsMember2024-12-310001809196imtx:ShorttermDepositsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001809196ifrs-full:SharePremiumMemberifrs-full:OrdinarySharesMember2025-04-012025-06-300001809196imtx:OtherCurrentNonCurrentAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001809196ifrs-full:LeaseLiabilitiesMember2025-06-300001809196ifrs-full:PreviouslyStatedMember2024-06-300001809196imtx:BMSCollaborationAgreementMember2025-04-012025-06-300001809196imtx:CollaborationAgreementsMember2025-01-012025-06-300001809196ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2025-04-012025-06-300001809196imtx:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001809196ifrs-full:SharePremiumMember2023-12-310001809196imtx:ModernaCollaborationAgreementMember2025-04-012025-06-300001809196imtx:IFRS7NotApplicableAndIFRS16Memberimtx:OtherCurrentNonCurrentAssetsMember2024-12-3100018091962024-01-012024-03-310001809196imtx:GeneralAndAdministrativeExpensesMember2025-01-012025-06-300001809196imtx:MatchingStockOptionsMember2025-01-012025-06-300001809196ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember2024-04-012024-06-300001809196country:USimtx:BMSCollaborationAgreementMember2025-01-012025-06-300001809196country:USimtx:BMSCollaborationAgreementMember2024-01-012024-06-300001809196imtx:GeneralAndAdministrativeExpensesMember2025-04-012025-06-300001809196imtx:PerformanceBasedOptionsMemberimtx:TrancheOneMember2025-06-300001809196ifrs-full:OtherReservesMember2025-01-012025-06-3000018091962024-03-310001809196ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001809196imtx:IFRS7NotApplicableAndIFRS16Memberifrs-full:LeaseLiabilitiesMember2024-12-310001809196imtx:ResearchAndDevelopmentExpensesMember2024-01-012024-06-3000018091962025-03-310001809196imtx:PerformanceBasedOptionsMemberimtx:TrancheThreeMember2025-06-300001809196ifrs-full:SharePremiumMember2025-06-300001809196ifrs-full:BottomOfRangeMember2024-12-310001809196ifrs-full:SharePremiumMember2025-01-012025-06-300001809196imtx:CashAndCashEquivalentMember2024-12-310001809196ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberimtx:OtherCurrentLiabilityMember2025-06-3000018091962024-06-300001809196imtx:ResearchAndDevelopmentExpensesMember2025-04-012025-06-300001809196imtx:CashAndCashEquivalentMember2025-06-300001809196imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember2024-12-310001809196imtx:RentalLandMember2025-04-012025-06-300001809196imtx:TradeTaxMemberimtx:ImmaticsBiotechnologiesGmbhMembercountry:DE2025-01-012025-06-300001809196country:DE2025-06-300001809196ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2025-01-012025-06-300001809196imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember2025-04-012025-06-300001809196ifrs-full:MajorOrdinaryShareTransactionsMemberimtx:PublicOfferingMember2024-01-222024-01-220001809196imtx:OtherCurrentNonCurrentAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001809196imtx:PerformanceBasedOptionsMember2025-06-3000018091962025-01-012025-06-300001809196ifrs-full:RetainedEarningsMember2025-06-300001809196imtx:IFRS7NotApplicableAndIFRS16Member2024-12-310001809196ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberimtx:AccountsPayablesMember2025-06-300001809196ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2025-06-300001809196ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember2024-01-012024-06-300001809196imtx:ImmaticsBiotechnologiesGmbhMembercountry:DEimtx:CorporateTaxMember2025-01-012025-06-300001809196country:USimtx:ModernaCollaborationAgreementMember2025-01-012025-06-300001809196ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberimtx:OtherCurrentLiabilityMember2024-12-310001809196imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember2025-01-012025-06-300001809196ifrs-full:TopOfRangeMember2024-06-300001809196ifrs-full:TopOfRangeMember2025-06-300001809196imtx:IFRS7NotApplicableAndIFRS16Memberimtx:OtherCurrentLiabilityMember2024-12-310001809196imtx:ModernaCollaborationAgreementMember2025-01-012025-06-300001809196imtx:RentalLandMember2024-01-012024-06-300001809196ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2024-01-012024-06-300001809196imtx:PerformanceBasedOptionsMember2025-01-012025-06-300001809196imtx:CollaborationAgreementsMember2025-04-012025-06-3000018091962024-01-012024-06-300001809196imtx:NonInterestBearingLiabilityMember2025-01-012025-06-300001809196ifrs-full:RetainedEarningsMember2024-01-012024-06-300001809196ifrs-full:PreviouslyStatedMember2024-01-012024-06-300001809196imtx:ReorganizationMember2024-12-310001809196imtx:PerformanceBasedOptionsMemberimtx:TrancheTwoMember2025-06-300001809196imtx:MatchingStockOptionsMember2024-12-310001809196imtx:AccountsPayablesMember2025-06-30iso4217:EURimtx:Segmentxbrli:pureimtx:Warrantsxbrli:sharesiso4217:EURiso4217:USDiso4217:EURxbrli:sharesutr:Yiso4217:USDiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

August 13, 2025

Commission File Number: 001-39363

IMMATICS N.V.

Paul-Ehrlich-Straße 15

72076 Tübingen, Federal Republic of Germany

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On August 13, 2025, Immatics N.V. (the “Company”) issued an interim report for the three- and six-month period ended June 30, 2025, which is attached hereto as Exhibit 99.1, and issued a press release announcing the second quarter 2025 financial results and business update for the Company, which is attached hereto as Exhibit 99.2. In addition, the Company made available an updated investor presentation. A copy of this presentation is attached hereto as Exhibit 99.3.

INCORPORATION BY REFERENCE

This Report on Form 6-K (other than Exhibit 99.2 and Exhibit 99.3 hereto) including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Nos. 333-249408, 333-265820, 333-280935 and 333-288466) and the registration statements on Form F-3 (Registration Nos. 333-240260, 333-274218 and 333-286151) of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBITS

Exhibit Number	Description
99.1	Immatics N.V. interim report for the three- and six-month period ended June 30, 2025.
99.2	Press release dated August 13, 2025.
99.3	Corporate presentation dated August 13, 2025.
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document
101.SCH	Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
104	Cover page formatted as Inline XBRL and contained in Exhibit 101

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		IMMATICS N.V.
Date: August 13, 2025		by:	/s/ Harpreet Singh
			Harpreet Singh
			Chief Executive Officer

3

FAQ

What did Immatics N.V. (IMTX) file on this Form 6-K?

Immatics N.V. filed a Form 6-K as a foreign private issuer, furnishing an interim report for the three- and six-month period ended June 30, 2025, a press release on second quarter 2025 financial results and business update, and an updated corporate investor presentation.

Which financial period does Immatics’ interim report on this Form 6-K cover?

The interim report attached to the Form 6-K as Exhibit 99.1 covers Immatics’ three- and six-month period ended June 30, 2025.

What exhibits are included with Immatics N.V.’s August 13, 2025 Form 6-K?

The Form 6-K includes Exhibit 99.1 (interim report for the three- and six-month period ended June 30, 2025), Exhibit 99.2 (press release dated August 13, 2025), Exhibit 99.3 (corporate presentation dated August 13, 2025), and technical Inline XBRL exhibits 101 and 104.

How is this Immatics (IMTX) Form 6-K incorporated by reference into other SEC registrations?

The Form 6-K, other than Exhibits 99.2 and 99.3, including Exhibit 99.1, is incorporated by reference into Immatics N.V.’s registration statements on Form S-8 (Registration Nos. 333-249408, 333-265820, 333-280935 and 333-288466) and Form F-3 (Registration Nos. 333-240260, 333-274218 and 333-286151).

Does this Immatics Form 6-K include a business update in addition to financial information?

Yes. Alongside the interim financial report, the company furnished a press release announcing second quarter 2025 financial results and a business update, as well as an updated corporate presentation.

Who signed the Immatics N.V. Form 6-K filed on August 13, 2025?

The Form 6-K was signed on behalf of Immatics N.V. by Harpreet Singh, who is identified as the Chief Executive Officer.